Aravax has announced the appointment of Louise Peacock as its new Chief Regulatory and Quality Officer.
Peacock brings over 35 years of pharmaceutical industry experience to the role, which she takes on after previously serving as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics and Alladapt Immunotherapeutics.
Prior to this, Peacock held a variety of positions at Aimmune Therapeutics, culminating in her role as Senior Vice President, Head of Pharma Research and Development.
She also previously served as Global Head of Regulatory Affairs at Circassia, and held senior positions at Abbott Laboratories, Auxilium Pharmaceuticals and Intermune earlier in her career.
Peacock, who will be based at the company’s Oxford, UK site, said: “I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 [an investigational immunotherapy for peanut allergy] and other products.”
Aravax’s Chief Executive Officer, Pascal Hickey, added: “Louise’s experience in regulatory affairs in the field of food allergy is unique… We are enormously excited that she is joining the Aravax team.”
